Skip to main content
QUCY
NASDAQ Life Sciences

David Lazar Converts Preferred Shares, Boosts Quantum Cyber Stake to 94.3%

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.422
Mkt Cap
$32.785M
52W Low
$0.3
52W High
$4.93
52W Position info
374% above low
Off High info
71% below high
Rel. Volume
Market data snapshot near publication time

QUCY has more than doubled off its 52-week low of $0.3.

Summary

David Lazar converted preferred shares into 55 million ordinary shares, raising his beneficial ownership to 94.3% of Quantum Cyber. The move solidifies his control during the company's pivot to cybersecurity and drone technology.


Key Events · Ownership and Investor Activity · QUCY

  • Preferred Shares Converted

    David Lazar converted 1M Series A, 1M Series B, 1M Series C, and 124,700 Series D preferred shares into 55,057,500 ordinary shares for no additional consideration.

  • Ownership Surges to 94.3%

    Lazar now beneficially owns 477M ordinary shares, including 196.9M shares issuable upon conversion of Series D and 225M upon conversion of Series E preferred shares, representing 94.3% of the outstanding class.

  • Voting Control Consolidated

    With 94.3% ownership, Lazar holds sole voting and dispositive power over nearly all shares, enabling unilateral decisions on future dilutive actions or corporate changes.

  • Context: Business Pivot and Dilution

    The conversion follows Quantum Cyber's pivot to cyber/drones, a $250M shelf registration, and recent insider selling, raising concerns about further dilution for remaining public shareholders.


Analysis · QUCY · Life Sciences

David Lazar, the controlling shareholder, converted millions of preferred shares into ordinary shares, pushing his beneficial ownership to 94.3%. This consolidation of voting power comes amid Quantum Cyber's radical pivot from life sciences to cyber/drones and a series of dilutive financings. The conversion increases the public float's vulnerability to further dilution, as Lazar now controls nearly all voting power and can unilaterally approve future share issuances.

At the time of this filing, QUCY was trading at $1.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.8M. The 52-week trading range was $0.30 to $4.93. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

QUCY - Latest Insights

QUCY
Aug 07, 2026, 6:51 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $1.47
Real-time Price: $1.48 info
Change: +$0.0143 (+0.98%) info
Market Cap: $32.785M info
QUCY
Jul 24, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.12
Real-time Price: $1.48 info
Change: +$0.3597 (+32%) info
Market Cap: $32.785M info
QUCY
Jul 06, 2026, 6:09 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.40
Real-time Price: $1.48 info
Change: +$0.0797 (+6%) info
Market Cap: $32.785M info
QUCY
Jul 01, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.54
Real-time Price: $1.48 info
Change: -$0.0603 (-4%) info
Market Cap: $32.785M info
QUCY
Jun 30, 2026, 3:13 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.56
Real-time Price: $1.48 info
Change: -$0.0803 (-5%) info
Market Cap: $32.785M info